{"url_path":"/sec/ppcb/8-k/2026-07-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/1517681/0001493152-26-033173-index.html","accession_number":"0001493152-26-033173","cik":"0001517681","ticker":"PPCB","issuer_name":"Propanc Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1517681/0001493152-26-033173-index.html","primary_entity_key":"0001517681","primary_entity_name":"Propanc Biopharma, Inc."},"word_count":92,"has_tables":true,"body_markdown":"**Item\n9.01 Financial Statements and Exhibits.**\n\n \n\n(d)\nExhibits:\n\n \n\n**Exhibit\nNo.**\n \n**Description**\n\n10.1\n \n[Director Agreement dated July 8, 2026 by and between Propanc Biopharma, Inc. and Carlo Campiciano](ex10-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\nDate:\nJuly 14, 2026\n**PROPANC\nBIOPHARMA, INC.**\n\n \n \n \n\n \nBy:\n*/s/\nJames Nathanielsz*\n\n \nName:\nJames\nNathanielsz\n\n \nTitle:\nChief\nExecutive Officer and Chief Financial Officer"}